<DOC>
	<DOC>NCT01235273</DOC>
	<brief_summary>The objective of the study is to determine whether treatment of the low IGF-1 syndrome in patients with CHF is able to modify some functional parameters, recognized as valid surrogate end-points of CHF progression.</brief_summary>
	<brief_title>Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>patients of either sex affected by CHF NYHA class IIIII, secondary to ischemic or idiopathic dilated cardiomyopathy age range 3080 years stable medications for at least two months prior to randomization, including ACE inhibitors or AT1 antagonists and betablockers (unless untolerated). LV ejection fraction 40% or less Peak VO2 consumption during a CPET â‰¤ 16 ml/kg/min. LV enddiastolic dimension 55 mm or more low IGF1 levels and a satisfactory response to an IGF1 generation test informed consent haemodynamic clinically significant primary valvular disease or significant congenital heart disease acute pericarditis/myocarditis inability to perform a bicycle exercise test Poorly controlled diabetes mellitus (HbA1c &gt;8.5) active proliferative or severe nonproliferative diabetic retinopathy active and/or history of malignancy evidence of progression or recurrence of an underlying intracranial tumor unstable angina or recent myocardial infarction (less than 5 months) severe liver disease serum creatinine levels &gt;2.5 mg/dl Inability to cooperate or administer the study drug Patients participating in any other clinical study, within 30 days prior to screening visit and/or during this particular study period</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>